A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates

S. Craig Risch, Susan McGurk, Michael D. Horner, Ziad Nahas, Susan D. Owens, Monica Molloy, Cynthia Gilliard, Scott Christie, John S. Markowitz, C. Lindsay DeVane, Jacobo Mintzer, Mark S. George

Research output: Contribution to journalArticlepeer-review

45 Scopus citations

Abstract

Cognitive impairment in multiple domains is common in patients with schizophrenia and may be a powerful determinant of poor functional ability and quality of life. We report a double-blind, placebo-controlled, cross-over study of donepezil augmentation in a schizoaffective disorder patient stabilized on olanzapine pharmacotherapy. The patient showed significant improvements in several cognitive measures and increased activation of prefrontal cortex and basal ganglia on functional MRI during the donepezil augmentation. In addition, the donepezil augmentation resulted in a reduction of depressive symptoms and in significant improvements in functional abilities and quality of life. Further studies of donepezil augmentation of neuroleptics in schizophrenia are warranted.

Original languageEnglish (US)
Pages (from-to)105-110
Number of pages6
JournalNeurocase
Volume7
Issue number2
DOIs
StatePublished - Jan 1 2001

Keywords

  • Cognition
  • Donepezil
  • Functional magnetic resonance imaging
  • Schizoaffective disorder

Fingerprint Dive into the research topics of 'A double-blind placebo-controlled case study of the use of donepezil to improve cognition in a schizoaffective disorder patient: Functional MRI correlates'. Together they form a unique fingerprint.

Cite this